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Other than annual vaccinations, there are few remedies for seasonal influenza virus infections. A recent study
in Cell from Dittmann et al. (2015) designed to reveal immune strategies against the flu has uncovered an
Achilles’ heel for influenza replication based on its requirement for host proteolytic machinery to enable effi-
cient spread.Each year, influenza viruses infect an
estimated 5%–10% of adults and 20%–
30% of children. It is well known that
infection of healthy individuals can re-
sult in incapacitating illness and can
lead to hospitalization and death among
high-risk groups whose immune systems
are compromised including pregnant
mothers, those with chronic illnesses,
infants, and the elderly, especially those
with heart and lung disease. Worldwide,
seasonal influenza is estimated to re-
sult in about 3–5 million cases of se-
vere illness, and about 250,000–500,000
deaths (WHO, 2014). The continuous
threat of new influenza viruses emerging
from animal reservoirs to infect the human
population is a major cause for concern,
as pandemic strains have the potential
to increase infection rates, spread rapidly
throughout the world, and exhaust sup-
plies of antiviral drugs. This threat is well
illustrated by the 1918 ‘‘Spanish flu,’’
which infected 20%–40% of the world-
wide population leading to approximately
50 million deaths (NIAID, 2014).
While the threat of seasonal influenza
virus can usually be ameliorated by vacci-
nation, there are few antiviral drugs that
can control an active epidemic, and the
evolution of resistance to existing drugs
is a persistent concern. One way to find
new targets for influenza virus control is
to seek a better understanding of innate
cellular immune mechanisms that have
evolved to curb virus replication. An
article published recently in Cell takes a
step in this direction by uncovering a
novel host mechanism that restricts the
spread of influenza virus infection by pro-
tease interference (Dittmann et al., 2015).
Influenza virus infection is initiated by
attachment of the virus to the host plasma
membrane, triggering endocytosis of the
virus particle (Figure 1). Fusion betweenthe virus envelope lipid bilayer and the
host endosomal membrane delivers the
viral RNA segments and associated pro-
teins into the cytoplasm where they can
enter the nucleus and begin genome repli-
cation and mRNA production that ulti-
mately produces progeny virus particles.
Influenza virus attachment and fusion
are mediated by a single viral transmem-
brane glycoprotein, hemagglutinin (HA),
which is synthesized as a precursor poly-
peptide (HA0) that is capable of attach-
ment to host cells, but inactive for
membrane fusion (Garten and Klenk,
1999; Steinhauer, 1999). The HA0 must
be cleaved by cellular proteases at a
specific protease recognition site to pro-
duce a mature, disulfide-linked dimer of
two polypeptide chains, HA1 and HA2
(Figure 1). This cleavage event converts
the inactive precursor protein into a
fusion-competent form that can be trig-
gered by low pH to mediate coalescence
of the viral membrane with the endosomal
membrane to initiate the infectious cycle.
Cleavage activation of HA is an important
determinant of influenza virus infection
that is essential for the virus to dissemi-
nate throughout the organism and be-
tween hosts. Highly pathogenic strains
that contain a cleavage peptide consist-
ing of multiple adjacent basic amino
acids, including avian influenza viruses,
are cleaved intracellularly by diverse
host cell proteases en route to the cell sur-
face. In contrast, mammalian influenza vi-
ruses and less pathogenic strains that
feature mono-basic cleavage peptides
are activated by secreted proteases in
the extracellular milieu. The spread of
these viruses relies on protease activation
outside the cell, and accordingly, interfer-
ence with HA0 cleavage prevents the
spread of human influenza by reducing
the infectious virus load and inhibitingCell Host & Microbe 1multi-cycle replication (Bo¨ttcher-Friebert-
sha¨user et al., 2014).
Nearly all nucleated mammalian cells
have the ability to produce and respond
to type I interferon (IFN; including IFNb
and multiple IFNa subtypes), the primary
cytokine that drives antiviral immunity
(Schneider et al., 2014). Virus infection is
detected by cellular pattern recognition
receptors, which activates IFN gene
transcription. Newly synthesized IFN is
secreted from the cell and can engage
the type I IFN receptor to initiate a JAK-
STAT signaling cascade that activates
the expression of diverse IFN-stimulated
gene (ISG) products. Together, the ISGs
produce a broadly effective antiviral state
in the cells that effectively restricts virus
replication in a non-specific fashion. The
IFN-mediated antiviral response is well
known as the first line of antiviral defense
that provides a primary barrier to virus
replication and also educates the subse-
quent innate and adaptive immune re-
sponses. Hundreds of ISGs in the virus-
induced transcriptional program combine
to mitigate virus replication, acting to
disrupt cellular RNA and protein synthe-
sis, activating cell death programs, and
altering metabolic pathways. Extracting
novel information regarding virus-specific
effectors from this pool of ISGs re-
quires thorough and focused molecular
dissection.
To investigate which—if any—ISG
products contribute specifically to the
antiviral response to influenza viruses,
Rice and colleagues employed a high-
throughput strategy to assess 401 known
ISGs for their ability to counteract in-
fluenza virus replication when expressed
individually during infection. Human lung
adenocarcinoma cells (A549) were trans-
duced with lentiviral vectors to ex-
press individual ISGs, and cells were7, March 11, 2015 ª2015 Elsevier Inc. 283
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Figure 1. Influenza Virus Replication Is Controlled by Host Cell Protease Activity
Host cell serine proteases (yellow Pac-Man) can cleave the HA0 precursor into the activated HA1+HA2,
allowing membrane fusion to initiate influenza virus replication and infectious spread. SERPINE1 gene
expression produces PAI-1 (blue wedge), which inactivates the serine proteases, preventing HA0 cleav-
age. Uncleaved HA0 can bind to cells, but cannot induce fusion, interfering with infection and spread.
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tory strain for influenza A virus (A/WSN/
33) at low multiplicity. High-throughput,
image-based analysis was used to deter-
mine the ability of the virus to spread to
adjacent cells in the presence or absence
of each expressed ISG.
A small number (19) of ISGs were found
to restrict the spread of influenza virus,
including several broadly acting antiviral
mediators involved in pattern recognition
and IFN production or signaling, known
influenza-directed ISG inhibitors, and
several ISGs whose antiviral activities
are poorly understood. One of these
genes, SERPINE1, encodes a secreted
serine protease inhibitor, PAI-1. Unre-
markable as an ISG itself, the mRNA is
present constitutively, and is only mildly
induced by influenza virus or IFN sti-
mulation. However, expression of the
SERPINE1 gene has a significant ability
to interfere with influenza virus spread.
Although implicated in many physiolog-
ical responses, PAI-1 has not previously
been recognized as a component of
innate antiviral immunity.
SERPINE1 expression was found to
inhibit the spread of a number of influenza
virus clinical strains indicating a broad
ability to restrict virus replication and in-
fectivity. While PAI-1 overexpression in-284 Cell Host & Microbe 17, March 11, 2015terferes with influenza virus spread and
reduces infectivity, interference with
PAI-1 expression increases the rate of
infection and significantly enhances virus
spread.
Mechanistic studies indicated that
PAI-1 does not alter early stages of virus
replication or particle budding from in-
fected cells, but instead the newly formed
progeny virus particles produced in the
presence of PAI-1 expression exhibited
reduced infectivity. Treatment of these
viruses with trypsin was able to restore
infectivity to the level of virus grown in
the presence of uninhibited protease,
suggesting that the defect in infectivity
was caused by uncleaved or immature
HA (Figure 1). Moreover, addition of puri-
fied PAI-1 to differentiated human ciliated
airway epithelium cultures was found to
reduce the cleavage of HA, and neutrali-
zation of PAI-1 with a specific antibody
resulted in the complementary effect of
increased HA cleavage. Several prote-
ases known to cleave HA, including uroki-
nase plasminogen activator (uPA; known
to be a target of PAI-1), trypsin, hu-
man airway trypsin, and tryptase, were
inhibited by PAI-1, implicating these pro-
teases as potential HA activators in vivo.
These findings indicate that PAI-1 can
restrict influenza virus spread by reducingª2015 Elsevier Inc.the HA cleavage maturation of progeny
particles, and that this mechanism oper-
ates in a physiologically relevant model
of airway epithelia.
The role of PAI-1 in control of influenza
virus maturation was also borne out
in animal models, where deficiency of
SERPINE1 results in an increase in virus
pathogenicity and lung virus titer com-
pared to controls. In humans, polymor-
phisms that create bleeding disorders
have been mapped to SERPINE1, and
heterozygous cells from these patients
have a partial deficiency in serum PAI-1
levels (Zhang et al., 2005). Infection of
these cells resulted in increased influenza
virus spread that could be reversed by
exogenous PAI-1.
These findings support the conclusion
that the serine protease inhibitor, PAI-1,
is a physiological regulator of influenza
virus spread and a previously unrecog-
nized component of the host ISG barrier
that restricts influenza virus infection
in vivo. As protease inhibitors have proven
to be valuable components of the antiviral
armamentarium, these findings may lead
the way to alternative therapeutic stra-
tegies for controlling human influenza
viruses.
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